Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
E: info@zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544
Zealand Pharma AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,960.92 | 121.35 | -1.50% |
| DAX 40 | 23,932.42 | 523.84 | -2.14% |
| Dow JONES (US) | 49,628.93 | 434.53 | -0.87% |
| FTSE 100 | 10,181.48 | 191.45 | -1.85% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,257.60 | 377.62 | -1.42% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,424.73 | 76.51 | -1.02% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |